March 9, 2012 — Boston Scientific Corp. announced the launch of the Promus Element everolimus-eluting coronary stent sys ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
March 6, 2012 — In a development that brings advanced combination therapy treatment of peripheral artery disease (PAD) t ...
March 06, 2012
February 24, 2012 – The U.S. Food and Drug Administration (FDA) this week granted the first coronary stent indication ...
February 24, 2012
February 20, 2012 — Medtronic announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity drug ...
February 20, 2012
February 1, 2012 — Boston Scientific announced the first patient use and European market launch of the Promus Element ...
February 01, 2012
January 23, 2012 – Boston Scientific Corp. said the U.S. District Court for the District of New Jersey has found all the ...
January 24, 2012
January 9, 2012 – A registry that includes every patient in Sweden having percutaneous coronary intervention (PCI) found ...
January 09, 2012
December 22, 2011 – Abbott today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe ...
December 22, 2011
December 12, 2011 - Boston Scientific recently announced U.S. Food and Drug Administration (FDA) approval for the Promus ...
December 12, 2011
December 9, 2011 — Abbott announced Thursday the initiation of ABSORB II, the first randomized, controlled, multi-center ...
December 09, 2011
November 21, 2011 — Micell Technologies Inc. announced the release of preliminary data from the first-in-human clinical ...
November 21, 2011November 15, 2011 – The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for ...
November 15, 2011November 15, 2011 – A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to ...
November 15, 2011
November 15, 2011 — Results of ADAPT-DES (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents) were ...
November 15, 2011November 15, 2011 — Researchers have found polymer-free amphilimus-eluting stents in de novo coronary artery lesions ...
November 15, 2011© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now